An Open Label Phase 1B/2 Trial of TRC105 and Sorafenib in Patients With Hepatocellular Carcinoma (HCC)

Trial Profile

An Open Label Phase 1B/2 Trial of TRC105 and Sorafenib in Patients With Hepatocellular Carcinoma (HCC)

Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 20 Jan 2018

At a glance

  • Drugs Carotuximab (Primary) ; Sorafenib
  • Indications Liver cancer
  • Focus Adverse reactions
  • Sponsors TRACON Pharmaceuticals
  • Most Recent Events

    • 20 Jan 2018 Results presented at the 2018 Gastrointestinal Cancers Symposium
    • 19 Jan 2018 Initial results presented in the TRACON Pharmaceuticals Media Release
    • 19 Jan 2018 According to a Tracon Pharmaceuticals media release, the completion of the enrollment of 33 patients expected by the end of 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top